{
    "2019-09-30": [
        [
            {
                "time": "2019-10",
                "original_text": "业绩向好+比较优势，医药有望再度成为“抱团焦点”||医药行业2019年10月份投资月报【兴证医药】",
                "features": {
                    "keywords": [
                        "业绩向好",
                        "医药",
                        "抱团焦点",
                        "投资月报"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-Q3",
                "original_text": "2019年医药三季报业绩前瞻||三季报预期向好，关注“变化”、稳守“核心资产”【兴证医药】",
                "features": {
                    "keywords": [
                        "三季报",
                        "业绩前瞻",
                        "预期向好",
                        "核心资产"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}